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Pulmonary tuberculosis usually has a smouldering onset and progression, and patients typically present
with the symptoms of cough, weight loss, anorexia, night sweats and malaise that is usually present for
a few weeks before presentation.
A 22-year old man presented with symptoms, signs and radiological features of an acute severe
community acquired pneumonia(CAP), a presentation that can delay the diagnosis of TB, and cause
institution of antibiotics that may transiently cause clinical improvement, only to be followed by dete-
rioration. We discuss the features that should make a physician suspect that possibility of TB, and
illustrate how in a high-burden country, even in the absence of these features, TB must be considered in
the differential diagnosis of any patient presenting with a CAP.
 2010 Elsevier Ltd. All rights reserved.1. Case report
A 22-year-old graduate student presented to the emergency
department with a 10-day history of high-grade fever, cough with
minimal yellowish expectoration and breathlessness. There was
no history of hemoptysis or weight loss and he had no history of
recent travel or exposure to persons with similar symptoms. His
past medical history was unremarkable. He was presumptively
treated by his local physician with a course of the antimalarial
Chloroquine for 3 days along with Levofoxacin 500 mg once a day
for 5 days, and reported an improvement during the course of the
treatment. However, 3 days after stopping the antibiotic, his sym-
ptoms signiﬁcantly deteriorated and he was referred for further
management.
On examination, he was febrile; his axillary temperature was
102 F. He was tachycardic, with a pulse of 120 beats/minute with
a regular rhythm. His respiratory rate was 40 breaths/minute, and
he was using his accessory muscles of respiration. His blood pres-
sure was 106/79 mm Hg, and his oxygen saturation, measured
using a pulse oximeter was 82 percent on room air. The examina-
tion of the respiratory system revealed decreased movements on
the left side, with an impaired note on percussion in the left inter-,
infra- scapular and axillary regions, and decreased breath sounds
on auscultation in the same areas.to), dr.arpanshah@gmail.com
hindujahospital.com
rved.The results of a laboratory evaluation for his acute febrile
hypoxemic respiratory illness were notable for a normal leucocyte
count of 7600 cells/mL (65% neutrophils, 25% lymphocytes, 5%
monocytes and 2% eosinophils). The erythrocyte sedimenta-
tion rate was 30 mm/h. His arterial blood gases revealed hypo-
xemia with respiratory alkalosis (pH-7.50, paCO2- 29 mmHg, paO2
e 65 mmHg, HCO3- - 20 mEq/litre, FiO2-60 percent delivered
through a bilevel positive pressure ventilator). He tested negative
for HIV by ELISA test. He failed to expectorate sputum for an
examination. A chest radiograph (Fig. 1) revealed a heterogenous
opaciﬁcation of the left upper- and mid- zones, a CT scan revealed
consolidation in the left upper lobe with inﬁltrates in the lingula
and left lower lobe (Fig. 2).
In the absence of a microbiological evidence, and with the
history of receiving a quinolone in the recent past, he was empir-
ically treated with intravenous ceftriaxone at a dose of 1 gm twice
a day along with azithromycin at a dose of 500 mg once a day. The
serological investigations sent for Chlamydia and Mycoplasma
were reported negative, as were the tests for urinary legionella
and pneumococcal antigens. His throat swab for the H1N1 virus
was negative.
Despite improvement in oxygenation with bilevel positive
pressure ventilation, he continued to remain febrile and tachypneic
after 5 days of the above therapy, and a decision was taken to
perform a ﬁberoptic bronchoscopy with bronchoalveolar lav-
age(BAL) for a microbiological diagnosis. The gram stain on the
specimen revealed gram-positive cocci along with weakly-gram
positive rods that prompted the microbiologist to perform a Z-N
staining that revealed acid-fast bacilli.
Fig. 1. Chest radiograph revealing consolidation of the left lung.
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four-drug antituberculous therapy. He responded well clinically,
and after being afebrile for 72-h was discharged a week after
starting the antituberculous treatment. A culture of the BAL ﬂuid at
3 weeks conﬁrmed the growth of Mycobacterium tuberculosis, and
sensitivity studies revealed it to be a strain susceptible to ﬁrst-line
drugs. At last follow-up, he has shown satisfactory clinical, micro-
biological and radiological recovery and was declared cured after
completing six months of treatment.2. Discussion
Tuberculosis, a disease caused by the bacillus M. tuberculosis
affects 9.4 million individuals and is responsible for the death of 1.8
million individualsacross theworldannually.1Thediseaseusuallyhas
a smouldering onset and progression, primarily due to the bacilli
multiplying once every 18e24 h, a duration much longer than that
taken by most pathogenic bacteria. Patients usually present with the
symptoms of cough, weight loss, anorexia, night sweats and malaise
that usually is present for a few weeks before presentation.
However, in relatively rare circumstances the disease canpresent
as an acute pneumonia with respiratory failure, masquerading asFig. 2. CT scan of the chest revealing consolidation with air bronchogram in the left
lingula.a community acquired pneumonia(CAP). The incidence of TB being
diagnosed among patients presenting with clinical and radiological
signs of a CAP has varied across series and can be as high as 35
percent of microbiologically conﬁrmed pneumonias, the incidence
being higher in the HIV-positive subgroup of patients.2,3 The inci-
dence of acute respiratory failure secondary to such an acute
pneumonia has been reported to be close to 1.5% among patients
hospitalized with pulmonary TB.4 The acute presentation of TB can
result from the primary infection, progressive primary disease,
reactivation of latent TB, or atlectasis caused by the effects of
compression or rupture of enlarged tuberculous lymph nodes.
TB is seldom thought of when the patient presents as an acute
pneumonia with respiratory failure, and the results of this are
twofold: Firstly, the patient gets treated with antibiotics, a variety
of which are known to have antituberculous effects, resulting in
transient improvement of the clinical picture. The most potent of
the antituberculous antibiotics are ﬂuoroquinolones, recom-
mended in the guidelines as one of the ﬁrst-line drug options in the
management of hospitalized patients with community acquired
pneumonia.5 The empiric use of antibiotics in the absence of an
index of suspicion for TB results in delays in diagnosis and insti-
tution of antituberculous therapy, and such delays are known to
cause increased morbidity and mortality, and increase the risk of
forward transmission.6 The second, and equallyworrisome result of
the use of ﬂuoroquinolones in the management of tuberculosis
misdiagnosed as community acquired pneumonia, is the acquisi-
tion of resistance to ﬂuoroquinolones during the period that the
bacillary load is exposed to monotherapy with the drug. A course of
ﬂuoroquinolone monotherapy for as short a duration as 13 days has
been found to select resistant mutants.7 Fluoroquinolones are one
of the most potent drugs in the treatment of multidrug resistant
TB, and propagation of resistance would accelerate the selection
of XDR- and pre-XDR mutants.
There are clues that should be looked for while assessing the
probability of tuberculosis in any patient diagnosed with a
community acquired pneumonia. Chronicity of symptoms, prese-
nce of pleural effusions, unsatisfactory response to standard
empiric antibiotics that cover the commonest pathogens or a tran-
sient improvement with the use of ﬂuoroquinolones followed by
deterioration on cessation of therapy, a history of prior tuberculosis
or close contact with a patient suffering from tuberculosis, a normal
leucocyte count, weakly gram-positive or gram-neutral rods on
sputum smear examination should alert the physician to the pos-
sibility of tuberculosis. In addition to these clues, underlying
conditions that pre-dispose to infection and increase the risk of
reactivation of latent TB such as diabetes, renal failure, gastrectomy
and immunosupressed conditions (HIV, corticosteroid therapy,
tumor necrosis factor e alpha inhibitor therapy, post-transplan-
tation state) should be speciﬁcally looked for, and an increased
index of suspicion for TB is warranted in the presence of any of such
predisposing factors.8 It is especially important to strongly suspect
TB in the differential diagnosis of CAP in countries that are endemic
for TB and among immigrants from such countries.
The treatment of pulmonary tuberculosis does not change based
on the severity of the initial presentation, and the presence of
respiratory failure does not warrant a change in the standard
treatment of TB that comprises an intensive phase, consisting of 2
months of Rifampicin (10 mg/kg/day), Isoniazid (5 mg/kg/day),
Ethambutol (15e20 mg/kg/day) and Pyrazinamide (25e30 mg/kg/
day) followed by a four-month course of Rifampicin and Isoniazid.9
The beneﬁcial effects of the addition of corticosteroids in the
presence of respiratory failure are not proven, and not recom-
mended by standard guidelines.
The case highlights the fact that pulmonary tuberculosis, though
commonly a diseasewith a subacute smouldering presentation, can
L.M. Pinto et al. / Respiratory Medicine CME 4 (2011) 138e140140occasionally masquerade as an acute community acquired pneu-
monia with respiratory failure, and should be entertained as
a possible differential diagnosis in any patient with CAP. Fluo-
roquinolones, despite being advocated in guidelines, should be
discouraged in the treatment of CAP, especially in areas endemic for
TB, not only because they delay the diagnosis of the disease,
but also because they cause the selection of resistant mutants in
cases where the CAP is due to TB. TB presenting as an acute
pneumonia with respiratory failure is treated in the same manner
as pulmonary TB presenting in other forms, and the beneﬁts of the
adjunctive use of corticosteroids are not proven and therefore,
not routinely recommended.
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